AstraZeneca’s hypertension drug baxdrostat, branded as Baxfendy, has received approval from the U.S. Food and Drug Administration, opening a new treatment pathway for millions of patients whose high blood pressure remains uncontrolled despite existing therapies. The Anglo-Swedish pharmaceutical company announced the regulatory clearance on Monday, May 18, positioning the drug as a significant commercial addition to its cardiovascular portfolio.
The FDA approval permits Baxfendy to be used in combination with other antihypertensive medicines. AstraZeneca has projected that the drug will generate more than $5 billion in peak annual sales.
Baxfendy works by inhibiting the production of aldosterone, a hormone known to elevate blood pressure and heighten the risk of heart and kidney complications. This mechanism sets it apart from older classes of antihypertensive treatments such as diuretics and ACE inhibitors, which do not directly address hormonal contributors to elevated blood pressure.
Beyond hypertension, baxdrostat is currently under investigation as a potential treatment for chronic kidney disease and heart failure, broadening its prospective clinical utility.
The FDA’s approval of Baxfendy is grounded in data from a late-stage clinical trial evaluating the drug in patients with uncontrolled or treatment-resistant hypertension. In that study, a 2 mg dose of Baxfendy added to standard treatment reduced systolic blood pressure by 9.8 millimetres of mercury (mmHg) from baseline at 12 weeks, after adjusting for placebo. At the 1 mg dose, systolic blood pressure the pressure exerted on arteries during the heart’s pumping action was reduced by 8.7 mmHg.
The Baxfendy FDA approval places AstraZeneca ahead of U.S. biotech Mineralys Therapeutics, which is developing a rival aldosterone inhibitor called lorundrostat. Mineralys’ drug is currently under FDA review, with a regulatory decision anticipated in December.
AstraZeneca originally acquired baxdrostat through its $1.8 billion acquisition of CinCor Pharma in February 2023.
The global burden of hypertension underscores the commercial and clinical relevance of this approval. According to the World Health Organization’s latest estimates, approximately 1.4 billion people worldwide are affected by high blood pressure, making it a leading cause of premature death globally. In the United States alone, nearly half of all adults roughly 120 million people live with hypertension, according to government data.
For healthcare executives and payers, the entry of Baxfendy into the U.S. market represents a new option for a patient population that has long lacked effective alternatives when standard treatments fall short. With uncontrolled hypertension remaining a persistent clinical challenge, the arrival of an aldosterone inhibitor with robust trial data and a clear differentiated mechanism adds a meaningful tool to the cardiovascular treatment landscape.
